ArticleFrontiers in pediatrics2023

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.

Ekaterina Alexeeva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.